News Sentiment

SMMT sentiment intelligence

Summit Therapeutics PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.81 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-9.4% over one week, +0.4% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -9.4% Price reacting lower
Trend fit Trend inactive 0.4% over four weeks
Fair value -2.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 35
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 7
Quartr 5
TradingView 4
simplywall.st 4
GuruFocus 3
Stock Traders Daily 3
BioSpace 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 19
Regulatory and legal 4
Deals and strategy 2
Analyst action 2
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Sahm Direct company coverage

Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?

Summit Therapeutics (SMMT) recently canceled a US$500 million public offering, causing its shares to fall by over 14% in 30 days, despite significant three-year gains. The cancellation raises questions about the stock's valuation, as some estimates suggest it is 51.2% undervalued

Tone
Positive 63/100
Event
Market update
Published
27 Jun 2026 04:39
Source
Sahm
CFO.com Direct company coverage

Summit Therapeutics finance chief tops list of public CFO pay in 2025

Manmeet Soni, CFO of oncology firm Summit Therapeutics, was the highest-paid finance chief among publicly traded American firms in 2025, with total compensation near $250 million. This compensation was largely driven by performance-based stock awards. The report by C-Suite Comp a

Tone
Positive 64/100
Event
Market update
Published
23 Jun 2026 20:39
Source
CFO.com
Investing.com Direct company coverage

Bernstein raises Summit Therapeutics stock price target on trial outlook

Bernstein SocGen Group has increased its price target for Summit Therapeutics (NASDAQ:SMMT) to $9.80 from $7.70, while maintaining an "Underperform" rating, based on an increased probability of success for its HARMONi-3 trial. The firm’s analysis assumes that results from Akeso’s

Tone
Neutral 50/100
Event
Analyst action
Published
22 Jun 2026 14:10
Source
Investing.com
Market source Direct company coverage

Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing

Summit Therapeutics Inc. (SMMT) withdrew a $500 million proposed public offering one day after its announcement, citing unfavorable market conditions. The offering was intended to fund research and development for ivonescimab, a bispecific antibody for cancer treatment that recen

Tone
Negative 40/100
Event
Market update
Published
22 Jun 2026 14:10
Source
Market source
Insider Monkey Direct company coverage

5 Most Promising Healthcare Stocks According to Wall Street Analysts

This article identifies Summit Therapeutics Inc. (NASDAQ: SMMT) as one of the most promising healthcare stocks according to Wall Street analysts. Summit's lead drug, ivonescimab, which targets cancer cells, recently showed positive Phase 3 data from a China-based lung cancer tria

Tone
Neutral 50/100
Event
Market update
Published
21 Jun 2026 00:10
Source
Insider Monkey
Intellectia AI Direct company coverage

SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides a financial overview of Summit Therapeutics Inc (SMMT), detailing its revenue breakdown, profitability margins, and a comparison with competitors like BMRN and ARWR. The company currently has no data on its revenue streams, and its gross, operating, and net

Tone
Neutral 50/100
Event
Earnings
Published
20 Jun 2026 08:09
Source
Intellectia AI
Stock Traders Daily Direct company coverage

Avoiding Lag: Real-Time Signals in (SMMT) Movement

Stock Traders Daily's Quantitative Research Desk provides an analysis of Summit Therapeutics Inc. (SMMT), highlighting near-term strong sentiment challenging persistent mid and long-term weakness. The article details an exceptional 87.0:1 risk-reward short setup and offers three

Tone
Negative 39/100
Event
Market update
Published
19 Jun 2026 22:34
Source
Stock Traders Daily
TradingKey Direct company coverage

Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Summit Therapeutics Inc (SMMT) has an earnings forecast score of 7.22, placing it in the 308th position out of 389 companies in the Biotechnology & Medical Research industry. Analysts have set an average price target of $34.50 for SMMT, with ratings predominantly suggesting a "Bu

Tone
Positive 67/100
Event
Earnings
Published
19 Jun 2026 06:39
Source
TradingKey